# Livtencity (maribavir) PDUFA date and FDA approval status

Canonical: https://sec-api.dev/pdufa/maribavir

> The FDA approved Livtencity (maribavir), sponsored by TAKEDA PHARMACEUTICAL CO LTD (TAK), on November 23, 2021.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: exact day, quarter only, month only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Key facts

| Field | Value |
| --- | --- |
| Drug | Livtencity (maribavir) |
| Codes | TAK-620 |
| Sponsor | TAKEDA PHARMACEUTICAL CO LTD (TAK) https://sec-api.dev/companies/tak/catalysts |
| Indications | [Cytomegalovirus (CMV)](https://sec-api.dev/indications/cytomegalovirus-cmv) |
| Modality |  |
| FDA designations | priority review |

## Timeline

### November 23, 2021: FDA approval

- Status: completed, approved. Date confidence: exact.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- openFDA Drugs@FDA: "NDA215596 ORIG-1 (Type 1 - New Molecular Entity): submission_status AP, submission_status_date 20211123, review_priority PRIORITY; sponsor_name TAKEDA PHARMS USA; product LIVTENCITY (MARIBAVIR)." https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA215596%22

### November 21, 2025: label expansion decision

- Status: completed, approved. Date confidence: exact.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- openFDA Drugs@FDA: "NDA215596 SUPPL-7 (Efficacy): submission_status AP, submission_status_date 20251121, review_priority STANDARD; sponsor_name TAKEDA PHARMS USA; product LIVTENCITY (MARIBAVIR)." https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA215596%22

### July 22, 2026: primary completion

- Status: completed. Date confidence: exact. Stage: 3. Indication: Cytomegalovirus (CMV).
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT06439342 (A Study of Maribavir in Chinese Adults With Cytomegalovirus (CMV) Infections): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2026-07-22 (ACTUAL); Lead Sponsor Takeda." https://clinicaltrials.gov/study/NCT06439342

### Jan to Apr 2027: topline data readout

- Status: scheduled. Date confidence: quarter. Stage: 3. Indication: Cytomegalovirus (CMV).
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT05319353 (A Study to Evaluate the Safety and Tolerability, Pharmacokinetics, and Antiviral Activity of Maribavir for the Treatment of Cytomegalovirus (CMV) Infection in Children and Adolescents Who Have Received a Hematopoietic Stem Cell Transplant (HSCT) or a Solid Organ Transplant (SOT)): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2027-01-18 (ESTIMATED); Lead Sponsor Takeda." https://clinicaltrials.gov/study/NCT05319353

### January 2027: primary completion

- Status: scheduled. Date confidence: month. Stage: 3. Indication: Cytomegalovirus (CMV).
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT05319353 (A Study to Evaluate the Safety and Tolerability, Pharmacokinetics, and Antiviral Activity of Maribavir for the Treatment of Cytomegalovirus (CMV) Infection in Children and Adolescents Who Have Received a Hematopoietic Stem Cell Transplant (HSCT) or a Solid Organ Transplant (SOT)): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2027-01-18 (ESTIMATED); Lead Sponsor Takeda." https://clinicaltrials.gov/study/NCT05319353

Calendar months: [January 2027](https://sec-api.dev/fda-calendar/2027-01)

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/pdufa/maribavir.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "Livtencity (maribavir) PDUFA date and FDA approval status." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/pdufa/maribavir

```bibtex
@misc{secapidev_pdufa_maribavir_20261116,
  title        = {Livtencity (maribavir) PDUFA date and FDA approval status},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/pdufa/maribavir}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_pdufa_maribavir_20261116","title":"Livtencity (maribavir) PDUFA date and FDA approval status","publisher":"sec-api.dev","URL":"https://sec-api.dev/pdufa/maribavir","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
